- Home
- PECO vs APLS Comparison
PECO vs APLS Comparison
Compare PECO & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PECO | APLS |
|---|---|---|
| Founded | 1991 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.2B |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PECO | APLS |
|---|---|---|
| Price | $41.98 | $41.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 21 |
| Target Price | ★ $39.71 | $33.59 |
| AVG Volume (30 Days) | 835.9K | ★ 62.6M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | 74.51 | ★ 112.50 |
| EPS | ★ 0.24 | 0.15 |
| Revenue | $726,594,000.00 | ★ $1,003,782,000.00 |
| Revenue This Year | $5.82 | N/A |
| Revenue Next Year | $3.81 | $18.19 |
| P/E Ratio | ★ $173.04 | $273.60 |
| Revenue Growth | 9.86 | ★ 28.46 |
| 52 Week Low | $32.84 | $16.83 |
| 52 Week High | $42.26 | $41.14 |
Technical Indicators
Market Signals| Indicator | PECO | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 65.57 | 84.57 |
| Support Level | $38.92 | $19.29 |
| Resistance Level | N/A | $41.14 |
| Average True Range (ATR) | 0.71 | 0.06 |
| MACD | 0.17 | -0.65 |
| Stochastic Oscillator | 87.41 | 58.33 |
Price Performance
Historical ComparisonAbout PECO Phillips Edison & Company Inc.
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).